Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03806985
Other study ID # 1607018057.B
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 28, 2019
Est. completion date June 27, 2023

Study information

Verified date October 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of oral psilocybin in post-traumatic headache. Subjects will be randomized to receive placebo, low dose psilocybin, or high dose psilocybin on two separate test days approximately 14 days apart. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. Blood samples will be drawn at various timepoints to measure levels of inflammatory peptides.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date June 27, 2023
Est. primary completion date June 27, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis of post-traumatic headache - Typical pattern of headache attacks with approximately two attacks or more weekly - Attacks are managed by means involving no more than twice weekly triptan use Exclusion Criteria: - Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis) - Axis I psychotic disorder in first degree relative - Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology - Pregnant, breastfeeding, lack of adequate birth control - History of intolerance to psilocybin, LSD, or related compounds - Drug or alcohol abuse within the past 3 months (excluding tobacco) - Urine toxicology positive to drugs of abuse - Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days - Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks - Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks - Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo oral capsule
microcrystalline cellulose capsule
Low Dose Psilocybin
0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
High Dose Psilocybin
0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)

Locations

Country Name City State
United States VA Connecticut Healthcare System West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute change in pain intensity 4-tiered pain score (0=none, 1=mild, 2=moderate, 3=severe) Measured at 0, 1, 2, 4, and 24 hours after drug administration
Primary Acute change in nausea/vomiting 4-tiered pain score (0=none, 1=mild, 2=moderate, 3=severe) Measured at 0, 1, 2, 4, and 24 hours after drug administration
Primary Acute change in photophobia 4-tiered pain score (0=none, 1=mild, 2=moderate, 3=severe) Measured at 0, 1, 2, 4, and 24 hours after drug administration
Primary Acute change in phonophobia 4-tiered pain score (0=none, 1=mild, 2=moderate, 3=severe) Measured at 0, 1, 2, 4, and 24 hours after drug administration
Primary Acute change in functional disability 4-tiered pain score (0=none, 1=mild, 2=moderate, 3=severe) Measured at 0, 1, 2, 4, and 24 hours after drug administration
Primary Time to first headache attack Measured in days Two weeks following each test session
Primary Time to last headache attack Measured in days Two weeks following each test session
Primary Change in headache attack frequency Average number (number per week) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in headache attack duration Average duration (measured in hours) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in pain intensity of headache attacks Average pain intensity (4-tiered pain score; 0=none, 1=mild, 2=moderate, 3=severe) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in intensity of nausea/vomiting during headache attacks Average intensity of nausea/vomiting (4-tiered pain score; 0=none, 1=mild, 2=moderate, 3=severe) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in intensity of photophobia during headache attacks Average intensity of photophobia (4-tiered pain score; 0=none, 1=mild, 2=moderate, 3=severe) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in intensity of phonophobia during headache attacks Average intensity of phonophobia (4-tiered pain score; 0=none, 1=mild, 2=moderate, 3=severe) From two weeks before first session to two weeks after second session using a headache diary
Primary Change in intensity of functional disability during headache attacks Average intensity of functional disability (4-tiered pain score; 0=none, 1=mild, 2=moderate, 3=severe) From two weeks before first session to two weeks after second session using a headache diary
Secondary Use of abortive/rescue medication number of times per week From two weeks before first session to two weeks after second session using a headache diary
Secondary Headache attack-free time Number of 24 hour days (may be non-consecutive) From two weeks before first session to two weeks after second session using a headache diary
Secondary Quality of life using the Centers for Disease Control (CDC) Health-Related Quality of Life Scale: Healthy Days Symptoms Module 4 questions scored 0 to 30 each; higher numbers indicate worse quality of life.
(1) pain-related impairment, (2) mood symptoms, (3) anxiety symptoms, and (4) lack of sleep Percent change for each measure as well as total score (range 0 to 120) will be calculated.
From two weeks before first session to two weeks after second session using a headache diary
Secondary Depression using Patient Health Questionnaire 9 (PHQ-9) 9 question self-report questionnaire to assess the presence of depression-related symptoms. Each question is rated on a scale of 0-3 (0 = Not at all; 1 = Several days; 2 = More than half the days; 3 = Nearly every day). Higher scores indicate greater presence of depression-related symptoms.
Total score is calculated. Total score 5-9 = minimal symptoms; total score 10-14 = Major Depression, mild; total score 15-19 = Major Depression, moderately severe; total score >20 = Major Depression severe.
From two weeks before first session to two weeks after second session using a headache diary
Secondary Suicide risk using the Columbia Suicide Severity Rating Scale (CSSRS) A 10-category assessment of suicidal ideation and behavior. 5 categories (scored "yes/no") relate to the presence of suicidal ideation. 5 categories (scored "yes/no") relate to the presence of suicidal behavior. A "yes" to any of the suicidal ideation categories indicates the presence of suicidal ideation; a "yes" to any of the suicidal behavior categories indicates the presence of suicidal behavior. From two weeks before first session to two weeks after second session using a headache diary
Secondary Psychedelic effects using the 5-Dimensional Altered States of Consciousness (5D-ASC) scale 94 questions scored 0 to 100 each; higher numbers indicate greater psychedelic effects Questions address 5 dimensions: (1) Oceanic boundlessness (score range 0-2700), (2) Dread of Ego Dissolution (score range 0-2100), (3) Visionary Restructuralization (score range 0-1800), (4) Auditory Alterations (score range 0-1600), and (5) Vigilance reduction (score range 0-1200) Score for each dimension as well as total score (range 0 to 9400) will be measured. Taken on each test day approximately 6 hours after drug administration
Secondary Change in blood pressure Maximum change from baseline during each test day (mmHg) Measured during each test session prior to drug administration, every 15 min in the first hour, every 30 min in the second hour, and then hourly for 4 hours or until resolution of psychedelic effects (~6 hours post drug)
Secondary Change in heart rate Maximum change from baseline during each test day (beats per minute) Measured during each test session prior to drug administration, every 15 min in the first hour, every 30 min in the second hour, and then hourly for 4 hours or until resolution of psychedelic effects (~6 hours post drug)
Secondary Change in peripheral oxygenation Maximum change from baseline during each test day (SpO2) Measured during each test session prior to drug administration, every 15 min in the first hour, every 30 min in the second hour, and then hourly for 4 hours or until resolution of psychedelic effects (~6 hours post drug)
Secondary Change in peripheral levels of calcitonin gene-related peptide (CGRP) Change from baseline during each test day (pg/mg protein) Measured during each test session prior to drug administration, and at 2 and 4 hours after drug administration
Secondary Change in peripheral levels of pituitary adenylate cyclase-activating peptide (PACAP) Change from baseline during each test day (pg/mg protein) Measured during each test session prior to drug administration, and at 2 and 4 hours after drug administration
See also
  Status Clinical Trial Phase
Recruiting NCT04369729 - Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Completed NCT03588364 - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine N/A
Recruiting NCT05378074 - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache N/A
Recruiting NCT05328635 - Post-traumatic Headache Multidisciplinary Study
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Recruiting NCT04614922 - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms N/A
Recruiting NCT05595993 - Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache N/A
Completed NCT03674398 - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology N/A
Completed NCT02965027 - Prazosin for Post-Concussive Headaches Phase 4
Active, not recruiting NCT05635656 - Digital Solutions for Concussion N/A
Recruiting NCT06015451 - Exercise in Postconcussion Symptoms and Posttraumatic Headache N/A
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Terminated NCT01053507 - Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Phase 4
Completed NCT02419131 - Cognitive-Behavior Therapy for Posttraumatic Headache N/A
Completed NCT05243953 - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache N/A
Completed NCT03056352 - Metoclopramide for Post-Traumatic Headache. A Pilot Study Phase 1/Phase 2
Recruiting NCT06132529 - A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
Completed NCT01854385 - Sumatriptan as Treatment for Post-traumatic Headache Phase 2
Completed NCT03523923 - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI) N/A
Recruiting NCT05378061 - Hypersensitivity to PACAP-38 in Post-Traumatic Headache N/A